Last reviewed · How we verify
NCT04766710
Community-Based Model for Delivery of Antiretroviral Therapy in Cambodia
NA trial testing Community-based ART delivery (CAD) in HIV Infections in 4,102 participants. Status unknown.
31 March 2023
Quick facts
| Lead sponsor | National University of Singapore |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 4,102 |
| Start date | 1 April 2021 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 March 2024 |
| Sites | 3 locations across Cambodia |
Drugs / interventions tested
- Community-based ART delivery (CAD)
- ART multi-month dispensing (MMD)
Conditions studied
- HIV Infections — all drugs for HIV Infections →
- AIDS — all drugs for AIDS →
Sponsor
National University of Singapore
Who can join
15 and older, any sex, with HIV Infections or AIDS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The community-based ART delivery (CAD) model will build on the existing framework to engage community action, operationalized in the current Global Fund-supported project. Community Action Workers (CAW), who are assigned to ART centers and conduct outreach work, are well-suited to administer CAD scheme. KHANA and the project partners all have implementation roles in the Global Fund-supported project and established working channels with the CAW. While the previous experiences suggest the CAD model's effectiveness, implementing it in Cambodia requires adaptation to its specific local context. The proposed project will be implemented as an implementation study in nine ART sites and supported by a concrete evaluation plan. KHANA Center for Population Health Research will lead the research component. The project has three strategic areas and corresponding deliverables as follows: A. The development of a locally-fitted model: bringing ART closer to the people living with HIV B. The research: formulation, evaluation, documentation, and dissemination of the evidence, knowledge, and lessons learned C. The scale-up: advocacy for the SOP development to replicate/scale-up the CAD model The project will benefit a wide range of stakeholders. The approximately 2,000 ART clients enrolled in the nine selected clinics will face less cost, time, and discrimination, which will also benefit their families. The clinics will have a reduced workload on site, and they would be able to improve the quality of care for the visiting clients. The Cambodian health system will obtain a CAD model tailored to the country's local context and develop Standard Operating Procedures for the scheme with readily involved stakeholders. The scale-up of the model will benefit all other ART clinics and clients in the country. The 36-months project starting from June 1, 2019, will include six months of start-up and baseline assessments, 24-month intervention, and six-month evaluation.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Community-based model for the delivery of antiretroviral therapy in Cambodia: a quasi-experimental study protocol.
Tuot S, Teo AKJ, Prem K, Chhoun P, et al · · 2021 · cited 7× · PMID 34362310 · DOI 10.1186/s12879-021-06414-y -
Impact of a community-based antiretroviral therapy delivery model for people living with HIV in Cambodia.
Tian Z, Chhoun P, Tuot S, Yam LYE, et al · · 2025 · PMID 41290647 · DOI 10.1038/s41467-025-66606-x -
Cost-effectiveness analysis of a community-based model for delivery of antiretroviral therapy to people with clinically stable HIV in Cambodia.
Yam LYE, Chhoun P, Tian Z, Nagashima-Hayashi M, et al · · 2025 · PMID 40623943 · DOI 10.1002/jia2.26476 -
Community-based model for the delivery of antiretroviral therapy in Cambodia: a quasi-experimental study protocol
Tuot S, Teo AKJ, Prem K, Chhoun P, et al · · 2021 · DOI 10.21203/rs.3.rs-497277/v1
Verify or expand the search:
- PubMed search for NCT04766710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV Infections
Currently open trials in the same condition.
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
- NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
- NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
- NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting
Other National University of Singapore trials
Trials by the same sponsor.
- NCT07519642 — Frailty Improvement Through Technology With Informal Caregiver Supported Exercise (FITWISE) for Pre-frail and Frail Comm · NA · not yet recruiting
- NCT07525492 — Die-logue Program for Community Dwelling Adults: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07375459 — Community-based Mobile-assisted Brief Intervention for Smoking Cessation · NA · recruiting
- NCT07444073 — Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock · not yet recruiting
- NCT07282041 — Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04766710 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National University of Singapore
- Last refreshed: 9 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04766710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing